NCT00390195 - Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC) | Biotech Hunter

Enrollment

134

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2011

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

RAD001 (everolimus)

Arm 1: 2.5, 5, 7.5 or 10 mg of RAD001 daily

DRUG

RAD001 (everolimus)

Arm 2: 20, 30, 50 or 70 mg of RAD001 daily

Trial Locations (2)

RECRUITING

National Cheng Kung University Hospital, Tainan City

ACTIVE_NOT_RECRUITING

Tri-Service General Hospital, Taipei